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Abstract
Atrial fibrillation (AF) is common in patients with kidney disease, with prevalence 
several times greater than in the general population. Anticoagulation agents are used 
to prevent thromboembolic events as a consequence of AF. Several randomized trials 
have established the efficacy of antithrombotic drugs for preventing stroke in patients 
with AF, with both antiplatelet agents and oral anticoagulants showing benefit. End-
stage kidney disease (ESKD) patients have known platelet defects/dysfunction and also 
receive heparin during their dialysis treatment, which contributes to their overall coagu-
lopathy. Warfarin being vitamin-K antagonist can augment calciphylaxis in patients with 
ESKD. Taken together, formal anticoagulation use in patients with ESKD may confer 
additional risk that is not appreciated in patients without kidney disease. In particular, 
patients on new oral anticoagulants show excess morbidity and mortality from bleeding 
when compared to warfarin.
Keywords: anticoagulation, warfarin, end-stage kidney disease, hemodialysis, atrial 
fibrillation, new oral anticoagulation
1. Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia that can lead to thrombus 
formation in the atria and atrial appendages. It also causes reduction in cardiac output and 
affected individuals are at increased risk of mortality. The prevalence of AF in patients with 
end-stage kidney disease (ESKD) is higher than in general population.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Patients with AF are managed with antiarrhythmic agents to control their heart rate and with 
anticoagulant agents to prevent thromboembolic events. The benefits of anticoagulation in 
patients with AF (without kidney disease) are well established; however, the benefits and 
safety of anticoagulation in patients with AF and ESKD are still not clear.
In this chapter, we discuss the prevalence of AF in ESKD and management of AF in these 
patients focusing on anticoagulation including the direct oral anticoagulants (DOACs).
2. Epidemiology
The 2010 Global Burden of Disease (GBD) study estimated that the prevalence of AF approxi-
mated at 33.5 million individuals worldwide [1]. In particular, AF is believed to affect between 
2.2 and 5.0 million Americans, 4.5 million Europeans and is estimated to affect 1.4% of 
Australians [1, 2]. The prevalence of AF is expected to increase globally over the next decade [3]. 
The prevalence of AF increases with age, occurring in approximately 1% of the population under 
60 years of age and 15% of the population over 80 years of age. Furthermore, the age-adjusted 
prevalence of AF is higher for men than women [1, 4]. In terms of complications of AF, ischemic 
stroke is the most common cause of cerebrovascular incident with 75% of these strokes directly 
linked to AF [3]. In addition, proportion of strokes from embolic sources increases with age, and 
greater than 35% of strokes in patients over 80 years of age are cardiac in origin, predominantly 
due to AF [3], making AF the commonest cause of stroke in this patients older than 80 years [1, 3, 4].
The health burden of renal disease is high for patients as well as for health services globally. 
The 2010 GBD study found that chronic kidney disease (CKD), which previously ranked 
27th in the list of causes of total number of global deaths in 1990, ranked 18th in 2010 [1, 5]. 
The incidence and prevalence of ESKD vary significantly across different countries. The inci-
dence of ESKD is increasing, with reports indicating doubling in the number of patients being 
treated for ESKD in Europe, the Americas, and Australia, with diabetes and hypertension being 
the most common causes in developed and many developing countries; however, glomerulo-
nephritis and “undetermined causes” were more common in Asia and sub-Saharan Africa [5].
Cardiovascular disease and its sequelae occur more frequently in patients with CKD, com-
pared to the general population, and it is often more severe [6]. Patients with impaired renal 
function (estimated glomerular filtration rate (eGFR) ≤80 mL/min) are deemed to be at higher 
risk for all cardiovascular events. Current literature examining the prevalence of AF in hemo-
dialysis (HD) patients varies widely, describing a range from 7 to 27% [4]. Furthermore, par-
oxysmal AF was present in 3.5%, persistent AF in 9.6% of patients and permanent AF in 13.9% 
of patients [4]. In a large cohort study conducted by Cheng-Huang et al., the prevalence of AF 
in patients receiving peritoneal dialysis and HD was examined [7]. The incidence rate ratios 
for AF were 2.07 and 1.78 in HD and PD groups, respectively. Additionally, after adjusting 
for age, gender and comorbidities, the hazard ratios for the AF risk were 1.46 and 1.32 in HD 
and PD groups, respectively.
In particular, in a study reported by Hohnloser et al., the risk of stroke in patients with CKD 
increased with decreasing eGFRs, the annual stroke rate was 1.05% in patients with an eGFR 
of >80 mL/min, 1.46% in patients with an eGFR of 50–80 mL/min and 2.39% in patients with 
an eGFR of ≤50 mL/min [8].
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3. Goals of therapy for AF
The mechanisms initiating and maintaining AF may be multifactorial in individual patients, 
including electrophysiological and structural abnormalities. The primary goals of therapy 
for AF are to control symptomatic effects of the disease and to prevent any disease-related 
complications such as thromboembolism and tachycardia-induced cardiomyopathy [9]. The 
management of AF therefore revolves around strategies for rate control, rhythm control and 
prevention of thromboembolic strokes. In relation to the former two strategies, multiple 
international guidelines, including the American College of Cardiology (ACC), the American 
Heart Association (AHA), European Society of Cardiology (ESC) and the Heart Rhythm 
Society (HRS) recommend that patients with no structural heart disease should be initiated 
with dofetilide, dronedarone, flecainide, propafenone, or sotalol, as these agents are found to 
have the lowest level of cardiac toxicity [9]. If first line therapy is contraindicated or shown to 
be ineffective, second-line therapy is considered and includes either amiodarone or catheter-
directed ablation [9]. Interestingly, amiodarone is considered as first line therapy in patients 
with substantial left ventricular (LV) hypertrophy as these patients are seen to be at increased 
proarrhythmic risk with most other first line antiarrhythmic drugs.
The prevention of thromboembolism including stroke prevention has been widely proven 
with the use of anticoagulants such as warfarin and DOACs. Stroke is seen to be the most 
common clinical thromboembolic event in patients with AF, with AF attributing to 36% of 
all strokes in individuals aged 80–89 years [10]. Furthermore, stroke occurring in patients 
who have AF tend to have a higher degree of severity as compared to those without AF [11]. 
Clinical markers predicting increased risk of stroke in patients with AF include previous his-
tory of transient ischemic attacks (TIA) or prior strokes, coronary artery disease, mitral ste-
nosis, left ventricular dysfunction, heart failure (HF), hypertension, diabetes mellitus, female 
gender and age more than 75 years [9].
Thrombus formation within the left atrial appendage occurs secondary to reduced blood flow 
velocities due to the loss of organized mechanical contraction in this anatomical area [12, 13]. 
Along with reduced flow velocity, other factors have also been attributed to the enhanced 
thrombogenicity in patients with AF. This includes reduced nitric oxide (NO) production in 
the left atrial endocardium, increased levels of the prothrombotic protein plasminogen activa-
tor inhibitor 1 (PAI-1), as well as elevated levels of β-thromboglobulin and platelet factor 4, 
von Willebrand factor (vWF), soluble thrombomodulin and fibrinogen [14].
4. Evaluation of embolic risk
All individuals who have AF are not at equally high risk for thromboembolic events, and sev-
eral predisposing clinical factors can identify those patients at relatively higher or lower risk. 
Risk stratification for embolic events assumes added importance, since the individual’s risk of 
embolic events needs to be carefully balanced against the risk of bleeding which is associated 
with anticoagulation. In patients without CKD, AF in association with any form of valvular 
heart disease (VHD) is considered for anticoagulation commencement as the stroke risk in 
this population subset is high [3, 15, 16]. Patients with nonvalvular heart disease (NVHD), 
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however, do not necessarily require anticoagulation, and the decision to anticoagulate for 
stroke prevention depends on their individual risk of stroke [15–17].
There are several risk scores that can be used to evaluate stroke and bleeding risk in the 
NVHD sub-group including the HAS-BLED score, the CHADS2 and CHA2DS2-VASc score and the ATRIA stroke risk score [18–21]. The CHADS2 stroke risk scoring system was devel-oped based on the analysis of 1773 patients in the National Registry for Atrial Fibrillation and 
in 2006 and was used in the ACC/AHA/ESC guidelines to tailor therapy for stroke prevention 
in AF [15]. The scoring system includes points for congestive heart failure, hypertension, age, 
diabetes and stroke [15, 20]. Previous stroke or TIA is the strongest predictor of stroke and 
equates for two points, whereas the other risk factors carry one point each. The final score 
measures the adjusted stroke rate per 100 patient-years [15, 18, 20]. The CHA2DS2-VASc score is an updated version of the CHADS2 score as not all patients with a CHADS2 score of 0 were found to be at low risk and was also noted that other risk factors that had been identified were 
not encompassed by this tool [18, 20, 22]. With the improvement to the CHA2DS2-VASc score, the 2012 ESC guidelines and 2014 ACC/AHA/HRS guidelines changed their recommenda-
tions to support the use of CHA2DS2-VASc score over the CHADS2 scoring system [18, 20, 22]. In addition to the CHADS2, the CHA2DS2-VASc acknowledges that stroke risk in patients with AF is related to age as a continuous variable, the higher risk of stroke in women, and incor-
porates risk associated with vascular disease, prior MI, complex aortic plaque, and peripheral 
arterial disease [18, 20, 22]. The CHA2DS2-VASc score states that antithrombotic therapy may be omitted for a score of 0, either oral anticoagulants, aspirin, or no antithrombotic therapy 
can be considered for a score of 1, and oral anticoagulation is recommended for patients with 
a prior stroke, TIA, or a score of 2 or more [3, 9, 15, 16, 18, 20, 22–26]. Although CHADS2 and CHA2DS2-VASc scores were useful tools in the past in assisting to quantify risk of stroke in patients with NVAF, recent studies have shown that the CHA2DS2-VASc score is only able to correctly predict strokes in approximately 68% of cases [3, 18, 22]. The HAS-BLED scoring sys-
tem was developed in 2010 as a result of the Euro Heart Survey and aims to assess the 1-year 
risk of major bleeding in patients with AF [18, 21]. The scoring system includes points for 
hypertension (Systolic >160 mmHg), abnormal renal function, liver function, stroke in past, 
bleeding, labile international normalized ratio (INR), age ≥65, consuming drugs and consum-
ing alcohol [19, 21]. The scoring system is based on a maximum of nine points with each risk 
factor worth one point each [18, 21]. A score of 3 or more indicating an increased 1-year bleed 
risk on anticoagulation is sufficient to justify caution or more regular review [19–21].
While there are other more contemporary risk assessment scoring systems available, such 
as the ABC (age, biomarkers, clinical history) stroke risk score as devised from Apixaban for 
Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARIS-TOTLE) 
study, their applicability is somewhat limited, as several key risk factors included are not 
routinely measured, and have also yet to be widely validated in population studies [27].
Information on how to best predict stroke risk in the ESKD population is limited and pre-
cludes the ability to identify patients at high risk for stroke. No stroke risk prediction scores 
have been specifically developed for patients with ESRD with AF. Existing thromboembolic 
and bleeding risk prediction scores show good standardization of stroke risk in the general 
population, but performs poorly in the ESKD population. McAlister et al. conducted a ret-
rospective large cohort study comparing the effectiveness of current thromboembolic and 
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bleeding risk prediction scores in patient with NVAF and CKD [28]. The seven risk predic-
tion models examined included CHADS2, CHA2DS2-VASc, R2CHADS2, ATRIA stroke, HAS-BLED, HEMORR2HAGES and ATRIA bleed. The study showed that the thromboembolic risk scores did not perform differently from each other, where the negative predictive value 
was not seen to be significantly different from each other. In terms of bleeding risk score, 
HEMORR2HAGES was the observed to be the most accurate with the highest c-statistic of 0.66 [28]. Furthermore, the study also showed that each of the seven risk prediction scores 
performed significantly better for patients with normal kidney function than in patients with 
CKD with performance significantly worsened as severity of kidney disease increased [28]. 
Therefore, the study suggests that current thromboembolic and bleeding risk prediction 
scores are inadequate for use in patients with CKD.
There is no difference in the indications for anticoagulation therapy between paroxysmal, 
persistent, or permanent AF. Clinical risk assessment tools such as the CHA2DS2-VASc score do not fully account for thromboembolic risk, and stroke can occur even after a sinus rhythm 
is restored by either pharmacological or electrical cardioversion.
5. Anticoagulation therapy in atrial fibrillation
As stipulated previously, no stroke risk prediction scores have been specifically developed 
for patients with CKD and AF. It has been shown, however, that patients with CKD and 
nonvalvular AF have a heightened stroke risk regardless of CHADS2DS2-VASc score, where 
80% of patients having scores of ≥2 [29]. Current ACC/AHA/ESC guidelines advise that for 
a CHADS2 score of ≥2 for either men or women, formal anticoagulation is recommended for patients [3, 9, 15, 16, 20, 22–26, 30]. Those with a CHADS2 score of 1, formal anticoagula-tion or aspirin alone should be considered in conjunction with patient specific comorbidities 
[3, 9, 15, 16, 20, 22–26]. Finally, the guidelines state for patients with a CHADS2 score of 0, no anticoagulation, neither formal nor antiplatelets, is recommended [3, 9, 15, 16, 20, 22–26]. In 
comparison with the American guidelines, the European guidelines recommend that males 
with a CHA2DS2-VASc score of ≥2 then anticoagulation should be used for stroke prevention, whereas those with a score of 1 should only be considered for anticoagulation, depending 
also on patient comorbidities and other risk factors [15, 20, 22–24]. Furthermore, for females, 
as female gender has been shown to be a weak risk factor for stroke in AF, guidelines advise 
that a CHA2DS2-VASc score of ≥3, then anticoagulation is recommended; however if the score is 2, then anticoagulation be considered [15, 20, 22–24]. If the CHA2DS2-VASc score is 0 in 
men and women or is 1 in women, neither formal anticoagulation nor antiplatelet therapy is 
advised or required [15, 20, 22–24].
5.1. Antiplatelets
There are few studies available that directly compare antiplatelet therapy, either single or 
dual agent, directly with formal anticoagulation. In a study conducted by Connely et al., it 
was investigated whether the addition of clopidogrel to aspirin in patients would reduce the 
risk of vascular events in patients with atrial fibrillation [11]. The primary end points exam-
ined included stroke, myocardial infarction, noncentral nervous system systemic embolism 
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and death from vascular causes. The study showed that in patients with AF where vitamin-K 
antagonists were deemed unsuitable, the addition of clopidogrel to aspirin reduced the risk 
of major vascular events, in particular stroke, by 28%; however, the combination increased the 
risk of major hemorrhage from 1.3 to 2.0% per year [10, 11].
The Stroke Prevention in Atrial Fibrillation (SPAF) II study was the only major study to show 
a positive outcome for use of aspirin in AF for stroke prevention [31]. The study showed that 
patients treated with aspirin had a statistically significant reduction of 42% in stroke rate over 
the placebo group [31]. In the more recent Apixaban Versus Acetylsalicylic Acid to Prevent 
Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin-K 
Antagonist Treatment (AVERROES) study, 5599 patients with atrial fibrillation who were at 
increased risk for stroke and for whom vitamin-K antagonist therapy was unsuitable were 
assessed and divided into groups whom received apixaban or aspirin [10]. The primary out-
come assessed in the study was the occurrence of stroke or systemic embolism. The study was 
halted at 18 months as a significant benefit from apixaban over aspirin was observed with a 
55% risk reduction in ischemic stroke [10]. Furthermore, it was also found that bleeding was 
comparable between aspirin and apixaban, 44 major bleeding events (a rate of 1.4% per year) 
among patients taking apixaban and 39 (1.2% per year) among those taking aspirin (hazard 
ratio with apixaban, 1.13; 95% CI, 0.74–1.75; P = 0.57) [10].
Olesen et al. examined aspirin’s use for stroke prevention in patients with AF and CKD. The 
retrospective cohort study found that aspirin was associated with an increased risk of stroke 
or systemic thromboembolism among patients who had any form of renal disease, (hazard 
ratio, 1.17; 95% CI, 1.01–1.35; P = 0.04) [9]. Furthermore, the risk of stroke or systemic throm-
boembolism in association with CKD was of the same magnitude when adjusted for all base-
line characteristics [9].
Aspirin, however, is still frequently used to reduce stroke risk in many patients with high 
CHA2DS2-VASc scores who would benefit from anticoagulation.
5.2. Vitamin-K antagonist
Vitamin-K antagonist, for example, warfarin, was first used as an anticoagulant in the 1960s 
when it was validated through multiple randomized, controlled clinical trials comparing it 
versus placebo or no therapy, that it had superior efficacy in reducing strokes in patients with 
NVAF [31, 32]. Warfarin’s effectiveness was confirmed in the pivotal 1992 Veterans Affairs 
Stroke Prevention in Nonrheumatic Atrial Fibrillation (SPINAF) trial [33]. This trial defini-
tively proved that warfarin reduced stroke rates in patients with NVAF by approximately 
70% and mortality by approximately 30% [33]. Furthermore, when investigated with regard 
to intention to treat, it was found that there was a 68% risk reduction in stroke for patients 
taking warfarin when compared to the control groups who were not anticoagulated [34, 35].
Although warfarin is extremely effective in reducing stroke and mortality, it is an incredibly 
difficult drug to use in clinical practice. Warfarin has a slow onset and offset of action and 
has multiple drug and food interactions. Warfarin requires constant monitoring to ensure the 
INR remains within the therapeutic range of 2–3. Studies have shown that an INR <2 carries 
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an increased risk of stroke, whereas an INR of >3 confers an increased risk of bleeding [31, 
32, 36, 37]. From an Australian perspective, the difficulties of warfarin’s clinical usage were 
seen in multicenter trials showing the time in therapeutic range (TTR) is near 70% at best, but 
more often found to be around 50–60% [38]. Interestingly there seems to be an increased risk 
of bleeding and intracranial hemorrhage (ICH) with warfarin in Asian populations, even in 
patients with an INR within the therapeutic range. This has seen some major centers in Asia 
adopt a lower therapeutic range of 1.5–2 [31, 32].
Formal anticoagulation using Warfarin has been shown to significantly reduce the incidence 
of stroke in CKD patients with AF. The Stroke Prevention in Atrial Fibrillation [SPAF-III] 
Study analyzed 516 AF participants with CKD and showed that warfarin was able to reduce 
ischemic stroke or systemic embolism by 76% (95% CI 42–90, P < 0.001) [39]. In a population-
based retrospective cohort study conducted by Mitesh et al., it was found that CKD patients 
requiring dialysis with AF, warfarin use, in comparison with no-warfarin use, did not reduce 
the risk for stroke however it was associated with a 44% higher risk for having a bleeding 
event, whereas warfarin use in nondialysis patients with AF was associated with a 13% lower 
risk for stroke with a 19% higher risk for bleeding event [32, 40]. Bleeding in this study was 
grouped and defined as intracerebral bleeding, gastrointestinal bleeding, intraocular bleeding, 
hematuria, and unspecified location of bleeding. This data should not be surprising though as 
it is well known that HD patients have both platelet and coagulation abnormalities and also 
have associated comorbidities such as uncontrolled hypertension and diabetes mellitus, all 
of which contribute to an increase in the risk for stroke and bleeding [32, 41]. Furthermore, 
HD patients usually also receive heparin during dialysis, which also adds to their increased 
risk for bleeding. Warfarin use in HD patients, through the inhibition of matrix Gla protein 
and Gas-6, thus causing calciphylaxis, can accelerate vascular calcification, which may also 
increase the risk for ischemic stroke [32, 42, 43]. This is further supported by a 134,410 patient 
retrospective study cohort by Chen et al. who compared ESRD patients requiring renal 
replacement therapy with AF receiving either monotherapy with antiplatelets or Warfarin 
with a control group who were not using either of the medications [44]. They showed that the 
incidence of ischemic stroke or TIAs was no different between the intervention group and the 
control group [44]. Furthermore, the results stayed unchanged after propensity match and 
also showed no beneficial effect of antiplatelet or warfarin therapy in any subgroups, such as 
age and gender [44].
5.3. Direct oral anticoagulation drugs
Currently available oral direct acting anticoagulants are the direct thrombin inhibitor dabiga-
tran, and the factor Xa inhibitors rivaroxaban and apixaban. Their clinical use in the normal 
population is favored due to their rapid onset and offset of action. Direct oral anticoagulations 
(DOACs) achieve full anticoagulation within 2 h of dosing, and are mostly excreted within 
24 h of taking the last dose. In addition to their appeal, none of the DOACs require routine 
monitoring to evaluate their extent of anticoagulation performance. There has been minimal 
evidence in investigating DOACs for stroke prophylaxis in ESKD patients with AF. All major 
trials, comparing DOACs to warfarin for AF and stroke prophylaxis, excluded patients with a 
calculated creatinine clearance rate of <25 or 30 mL/min [45, 46].
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The RE-LY study was the first open label study to compare dabigatran, a direct thrombin inhibi-
tor, to warfarin in patients with one or more risk factors for stroke [45]. The study concluded that 
a higher dose (110 and 150 twice daily) of dabigatran was superior to warfarin in reducing stroke 
and systemic embolism. The study also revealed the effect of creatinine clearance and renal 
function on dabigatran’s action and pharmacokinetics. Dabigatran is highly dependent on renal 
excretion with 80% being excreted unchanged in the urine. A 20% of patients in the RE-LY study 
had a CrCl of 30–50 mL/min (Patients with CrCl<30 were excluded). These patients had a higher 
risk of major bleeding compared to patients with a CrCl of >80 mL/min [46]. The RE-LY study 
also saw that warfarin-assigned patients with an eCrCl of 30–49 mL/min had a significant rate of 
major hemorrhage at 5.4% per year compared to other participants at 3.2% per year [45]. Large-
scale trials for dabigatran use in CKD patients are not available, and although dabigatran is 
partially removed by dialysis, it remains not recommended for anticoagulation during HD [47].
The Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin-K antago-
nism for prevention of stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial—
examined rivaroxaban versus warfarin in patients with two or more risk factors for a stroke. The 
study showed that rivaroxaban had similar efficacy to warfarin in reducing stroke and embolism 
but a significant reduction in ICH. The study was also able to show a statistically significant 
trend toward a decrease in all-cause mortality, as with other DOACs [48]. Patients with CrCl 
<30 mL/min were excluded from the trial, whereas patients with moderate renal insufficiency 
(CrCl of 30–50 mL/min) were included but given an adjusted dose of 15 mg daily based on data 
showing 25–30% higher residual serum concentration of rivaroxaban in these patients compared 
to patients with normal renal clearance [49, 50]. The ROCKET AF study was unable to demon-
strate noninferiority or superiority of rivaroxaban in patients with moderate renal insufficiency 
in comparison with warfarin therapy. The rates of stroke and systemic embolism were higher in 
patients with moderate renal impairment compared to patients with better renal function [47]. 
The ROCKET AF trial also examined the primary outcome of major hemorrhage in comparison 
with warfarin and was shown to occur in 3.2% of patients per year for those with an eCrCl of 
>50 mL/min as compared to 4.7% per year in those with an eCrCl of 30–49 mL/min [48]. There are 
no major trials for rivaroxaban therapy in patients with a creatinine clearance of <30 mL/min or 
on dialysis. Rivaroxaban has been shown to be able to be completely and immediately reversed 
with 50 U/kg prothrombin complex concentrate on patients with normal renal function [51].
Apixaban’s effectiveness was examined in the ARISTOTLE trial, which was similar to the 
other DOAC trials, included patients with one or more risk factors for stroke. The trial 
revealed that apixaban was superior to warfarin in stroke reduction and systemic embo-
lism [52]. Major and clinically relevant nonmajor bleeding was also found to be signifi-
cantly less with apixaban when compared to warfarin with ICH being also significantly 
reduced [3, 52]. Of the three DOACs available, only apixaban has proven to be statistically 
significant for reduction in total mortality when compared with warfarin, regardless of 
renal function.
The ARISTOTLE trial involved examining the efficacy of a apixaban in patients with creatinine 
of 133–221 μmol/L (1.5–2.5 mg/dL) and lower or creatinine clearance of >25 mL/min [45], and 
noted that the incidence of major bleeding events with apixaban was inversely related to renal 
functions [8]. Patients with moderate to severe renal insufficiency (creatinine 133–221 μmol/L 
or CrCl of <25 mL/min) were given 2.5 mg doses twice daily while patients with normal 
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renal function were given 5 mg twice daily. Bleeding episodes were higher in patients with 
moderate/severe renal failure when compared to the normal renal function group, however 
remained lower with apixaban compared to patients with renal impairment on warfarin. In 
terms of observing patients on warfarin, the ARISTOTLE trial showed that major hemorrhage 
was at least twice as likely among patients with an eCrCl of 25–50 mL/min compared with 
others [52]. The ARISTOTLE trial therefore eludes to apixaban being safe for oral anticoagula-
tion in AF patients with creatinine clearance of >25 mL/min, with dose adjustment as decided 
by the treating physician.
Again, there are no major trials investigating the effectiveness of apixaban on ESKD patients 
with stroke risks. Further research in this area is awaited. Apixaban like rivaroxaban is not 
dialyzable and therefore albeit the small renal excretion of 27 and 36%, respectively, they may 
build up in patients with ESKD [53]. Therefore, it is always advisable to continue monitoring 
patients with moderate to severe (CrCl 30–80 mL/min) for worsening renal function and pos-
sibility of toxicity.
6. Conclusions
In conclusion, patients with ESKD have higher prevalence of AF. In the absence of DOACs 
that can be used in patients with ESRD, vitamin-K antagonists still remain the gold stan-
dard for systemic anticoagulation in this group of patients. Anticoagulation with vitamin-K 
antagonist in patients with ESKD is challenging due to the adverse events such as increased 
risk of bleeding and augmentation of risk of calciphylaxis.
The risks of administering vitamin-K antagonists in patients with ESRD should be carefully 
weighed against benefits of these agents in preventing embolic episodes. Since newer DOACs 
may have a better benefit-risk profile in dialysis patients than vitamin-K antagonists, provided 
appropriate dose reductions are made, this strategy may yield more on-target anticoagula-
tion, reduce the risk of intracerebral bleeding, and not interfere with vascular calcification 
biology. Clinical trials with direct oral anticoagulant in dialysis patients are eagerly awaited. 
In addition, development of a DOAC that has nonrenal mode of excretion and can be safely 
given in patients on dialysis may also result in lower rates of bleeding complications, thereby 
shifting the risk-benefit balance toward systemic anticoagulation with this group of agents in 
the future.
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